AzurRx (AZRX) Corporate Media Kit

12 MS1819 Doses in Enteric Capsules # Patients Safety Primary Efficacy Endpoints Secondary Efficacy Endpoints Status • 2240 mg • 4480 mg 30 U.S., Poland CFA : MS1819 vs. PERT • Stool Consistency • Stool Quantity • Bowel Movements • Steatorrhea • Abdominal Discomfort • Weight Gain • CNA Initiated Q3 2020 Topline Data Anticipated Q1 2021 Open Label 2x2 Crossover Trial of MS1819 to assess the Safety and Efficacy in Enteric Capsules in Patients with Exocrine Pancreatic Insufficiency due to CF MS1819 Phase 2b Cystic Fibrosis OPTION 2 Study Initiated Q3 2020